Literature DB >> 26467147

Adipose Tissue-Derived Stem Cell Therapy for Post-Surgical Breast Reconstruction--More Light than Shadows.

Alessandra Bielli1, Maria G Scioli1, Pietro Gentile2, Valerio Cervelli2, Augusto Orlandi1.   

Abstract

Breast cancer remains the most common tumor in women, and new techniques for post- surgical breast reconstruction have been recently introduced. These new procedures include autologous fat grafting with or without the enrichment with autologous stromal vascular fraction (SVF), platelet-derived growth factors and insulin. The reported improvement of fat graft viability with these techniques likely depends on the presence in the SVF of multipotent resident adipose derived-stem cells (ASCs). The clinical advantage derives from the plasticity of ASCs and their ability to generate new functional adipose tissue and vessels. However, there is an ongoing debate regarding the possible interplay between breast tumor cells and resident or transplanted ASCs for their capacity to locally secrete growth factors. Most of the data in the literature concerning ASCs is derived from in vitro models, whereas the knowledge of ASC behavior in vivo remains scarce. Recent reports concerning SVF/ASC enrichment of fat graft did not describe any significant worsening of prognosis for patients undergoing those procedures. However, further studies and longer follow-ups are needed to specifically define technical procedures and to confirm the safety of procedures of SVF/ASC enrichment during post-surgical breast reconstruction.

Entities:  

Mesh:

Year:  2015        PMID: 26467147     DOI: 10.17219/acem/31673

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  8 in total

1.  Mediastinal germ cell tumors: new therapeutic insights.

Authors:  Amedeo Ferlosio; Alessandra Bielli; Augusto Orlandi
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 2.  Breast Cancer Therapy: The Potential Role of Mesenchymal Stem Cells in Translational Biomedical Research.

Authors:  Pietro Gentile
Journal:  Biomedicines       Date:  2022-05-19

3.  Analysis of oncological safety of autologous fat grafting after immediate breast reconstruction.

Authors:  Jae-Ho Chung; Ki-Jae Kim; Seung Pil Jung; Seung-Ha Park; Eul-Sik Yoon
Journal:  Gland Surg       Date:  2021-02

4.  Reconstruction of Alar Nasal Cartilage Defects Using a Tissue Engineering Technique Based on a Combined Use of Autologous Chondrocyte Micrografts and Platelet-rich Plasma: Preliminary Clinical and Instrumental Evaluation.

Authors:  Pietro Gentile; Maria G Scioli; Alessandra Bielli; Augusto Orlandi; Valerio Cervelli
Journal:  Plast Reconstr Surg Glob Open       Date:  2016-10-26

5.  Adipose-derived stem cell-mediated paclitaxel delivery inhibits breast cancer growth.

Authors:  Maria Giovanna Scioli; Simona Artuso; Carmen D'Angelo; Manuela Porru; Federico D'Amico; Alessandra Bielli; Pietro Gentile; Valerio Cervelli; Carlo Leonetti; Augusto Orlandi
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

Review 6.  Impact of the Different Preparation Methods to Obtain Human Adipose-Derived Stromal Vascular Fraction Cells (AD-SVFs) and Human Adipose-Derived Mesenchymal Stem Cells (AD-MSCs): Enzymatic Digestion Versus Mechanical Centrifugation.

Authors:  Pietro Gentile; Claudio Calabrese; Barbara De Angelis; Jacopo Pizzicannella; Ashutosh Kothari; Simone Garcovich
Journal:  Int J Mol Sci       Date:  2019-11-02       Impact factor: 5.923

7.  Epigenetic drugs induce the potency of classic chemotherapy, suppress post-treatment re-growth of breast cancer, but preserve the wound healing ability of stem cells.

Authors:  Andrew Zheng; Michelle Bilbao; Janhvi Sookram; Kimberly M Linden; Andrew B Morgan; Olga Ostrovsky
Journal:  Cancer Biol Ther       Date:  2022-12-31       Impact factor: 4.875

Review 8.  The Importance of Breast Adipose Tissue in Breast Cancer.

Authors:  Charu Kothari; Caroline Diorio; Francine Durocher
Journal:  Int J Mol Sci       Date:  2020-08-11       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.